Articles with "ccrcc progressed" as a keyword



A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy.

Sign Up to like & get
recommendations!
Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.6_suppl.tps708

Abstract: TPS708Background: Sitravatinib is a potent oral tyrosine kinase inhibitor that targets multiple receptor tyrosine kinase pathways including the vascular endothelial growth factor (VEGF), c-MET, and the Tyro3, Axl, and MER family. These pathways can allow… read more here.

Keywords: progressed prior; prior vegf; ccrcc progressed; therapy ... See more keywords